Astellas taps proteostasis in potential $1.2bn alliance
This article was originally published in Scrip
Assuming all milestones are met and options exercised, a new deal with Japan's Astellas will provide a bonanza for Proteostasis, being worth potentially more than $1.2bn to the privately-held US drug discovery venture.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.